In addition to anti-parkinsonian potential, KDS2010 effectively ameliorated memory impairment in the APP/PS1 transgenic mouse model of AD regardless of whether treatment was short-term (3 days) or long-term (30 days). This evidence concerns the gene APP and memory impairment.